CagriSema Blend (Cagrilintide / Semaglutide ) – 10mg

CagriSema is a dual peptide blend combining Cagrilintide and Semaglutide into a single 10mg lyophilized vial, pairing a long acting amylin receptor agonist with the most clinically documented GLP-1 receptor agonist in current research. iLab Pharma’s formulation mirrors the clinical development program being pursued by Novo Nordisk under the same CagriSema designation, where the combination of amylin and GLP-1 receptor co activation has generated significant research interest as a mechanistically distinct approach to metabolic regulation beyond what GLP-1 agonism alone achieves.

The pharmacological rationale behind the Cagrilintide and Semaglutide combination is grounded in their completely non overlapping receptor systems producing additive rather than redundant metabolic effects. Semaglutide’s GLP-1 receptor activation drives glucose dependent insulin secretion, pancreatic glucagon suppression, gastric emptying delay, and hypothalamic satiety signaling through arcuate nucleus GLP-1 receptor populations. The well documented incretin mechanism underpinning its regulatory approvals across diabetes and obesity indications. Cagrilintide’s amylin receptor activation through the calcitonin receptor RAMP complex produces complementary satiety signaling through area postrema and nucleus tractus solitarius pathways, additional gastric emptying regulation, and glucagon suppression through a completely separate receptor system from GLP-1. The two mechanisms converging on overlapping metabolic endpoints through independent molecular pathways that amplify each other’s activity without receptor competition or cross reactivity.

CagriSema’s research positioning within CSD’s metabolic peptide range is distinct from every other combination format in the catalogue. The Cagri-TRZ blend pairs Cagrilintide with Tirzepatide’s dual GIP/GLP-1 mechanism — adding GIP receptor activity to the amylin/GLP-1 combination. CagriSema pairs Cagrilintide with Semaglutide’s pure GLP-1 selectivity, isolating the amylin and GLP-1 receptor co-activation interaction without GIP receptor involvement. These two Cagrilintide containing blends serve complementary research purposes for studies examining the specific contribution of GIP receptor co activation to the amylin/incretin combined response, making both available from CSD an important research design advantage.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity across both peptide components before being made available, with COA documentation available on request. CSD stocks Cagrilintide and Semaglutide both as individual standalone compounds and across multiple combination formats, giving researchers the flexibility to examine each receptor mechanism in isolation or in various combination configurations from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside Cagri-TRZ and GLP-1 agonist compounds in comparative amylin and incretin receptor pathway studies. Browse CSD’s full peptide range for complete sourcing.